148 related articles for article (PubMed ID: 21669207)
1. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
[TBL] [Abstract][Full Text] [Related]
2. Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides.
Bøtkjaer KA; Byszuk AA; Andersen LM; Christensen A; Andreasen PA; Blouse GE
Biochemistry; 2009 Oct; 48(40):9606-17. PubMed ID: 19705874
[TBL] [Abstract][Full Text] [Related]
3. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
4. Rezymogenation of active urokinase induced by an inhibitory antibody.
Jiang L; Botkjaer KA; Andersen LM; Yuan C; Andreasen PA; Huang M
Biochem J; 2013 Jan; 449(1):161-6. PubMed ID: 23016918
[TBL] [Abstract][Full Text] [Related]
5. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.
Liu JN; Tang W; Sun ZY; Kung W; Pannell R; Sarmientos P; Gurewich V
Biochemistry; 1996 Nov; 35(45):14070-6. PubMed ID: 8916892
[TBL] [Abstract][Full Text] [Related]
6. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
7. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
Boutaud A; Castellino FJ
Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
[TBL] [Abstract][Full Text] [Related]
8. Structural investigations of recombinant urokinase growth factor-like domain.
Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
[TBL] [Abstract][Full Text] [Related]
9. Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation and constrained modelling.
Hu Y; Sun Z; Eaton JT; Bouloux PM; Perkins SJ
J Mol Biol; 2005 Jul; 350(3):553-70. PubMed ID: 15949815
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
11. Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties.
Sun Z; Liu JN
Proteins; 2005 Dec; 61(4):870-7. PubMed ID: 16231330
[TBL] [Abstract][Full Text] [Related]
12. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
14. Structure of human pro-chymase: a model for the activating transition of granule-associated proteases.
Reiling KK; Krucinski J; Miercke LJ; Raymond WW; Caughey GH; Stroud RM
Biochemistry; 2003 Mar; 42(9):2616-24. PubMed ID: 12614156
[TBL] [Abstract][Full Text] [Related]
15. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
16. A novel mode of intervention with serine protease activity: targeting zymogen activation.
Blouse GE; Bøtkjaer KA; Deryugina E; Byszuk AA; Jensen JM; Mortensen KK; Quigley JP; Andreasen PA
J Biol Chem; 2009 Feb; 284(7):4647-57. PubMed ID: 19047064
[TBL] [Abstract][Full Text] [Related]
17. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase.
Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654
[TBL] [Abstract][Full Text] [Related]
18. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC
Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831
[TBL] [Abstract][Full Text] [Related]
19. Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.
Botkjaer KA; Fogh S; Bekes EC; Chen Z; Blouse GE; Jensen JM; Mortensen KK; Huang M; Deryugina E; Quigley JP; Declerck PJ; Andreasen PA
Biochem J; 2011 Aug; 438(1):39-51. PubMed ID: 21635223
[TBL] [Abstract][Full Text] [Related]
20. The cleavage of pro-urokinase type plasminogen activator by stromelysin-1.
Orgel D; Schröder W; Hecker-Kia A; Weithmann KU; Kolkenbrock H; Ulbrich N
Clin Chem Lab Med; 1998 Sep; 36(9):697-702. PubMed ID: 9804393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]